Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration (Q57022663)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

title

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Amine Meliani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Florence Boisgerault

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Solenne Marmier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Fanny Collaud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Giuseppe Ronzitti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Christian Leborgne

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Helena Costa Verdera

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Marcelo Simon Sola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Severine Charles

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Alban Vignaud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Laetitia van Wittenberghe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Giorgia Manni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Olivier Christophe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Christopher Roy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Alicia Michaud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Petr Ilyinskii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Takashi Kei Kishimoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Federico Mingozzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

language of work or name

English

0 references

publication date

5 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

published in

Nature Communications

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

page(s)

4098

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

26 April 2020

start time

5 October 2018

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Monogenic diseases that can be cured by liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Gene therapy and pediatric liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

CD8(+) T-cell responses to adeno-associated virus capsid in humans

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Overcoming preexisting humoral immunity to AAV using capsid decoys

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Long-term effects of systemic gene therapy in a canine model of myotubular myopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

AAV2 gene therapy readministration in three adults with congenital blindness.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Human regulatory B cells in health and disease: therapeutic potential.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Adeno-associated virus vectors can be efficiently produced without helper virus

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

How to calculate sample size in animal studies?

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-06621-3

7 January 2021

Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30291246

12 December 2020

inferred from PubMed ID database lookup

Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30291246

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/S41467-018-06621-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

PubMed publication ID

30291246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30291246%20AND%20SRC:MED&resulttype=core&format=json